Jane Anderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jane Anderson has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Anne Sabin
Institute for Global Health, University College London, London, UK
40 shared publications Margaret Johnson
Royal Free Hospital London UK
36 shared publicationsMartin Fisher
34 shared publicationsChloe Orkin
26 shared publicationsClifford Leen
23 shared publications- Valerie Delpech
UK Health Security Agency, London, United Kingdom
23 shared publications
Latest Publications
- Open Access
- 11 May 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Application of machine-learning algorithms to identify the key determinants of risk for HIV, hepatitis C and hepatitis B in primary care settings
Testing for Blood-Borne-Viruses (BBVs) such as the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) is generally foc
- 11 May 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessApplication of machine-learning algorithms to identify the key determinants of risk for HIV, hepatitis C and hepatitis B in primary care settings
Testing for Blood-Borne-Viruses (BBVs) such as the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) is generally foc
- Open Access
- 31 December 2025
- Published by Wiley in HIV Medicine
- Vol. 27 (5) , 678-689
Supporting long‐term engagement in HIV clinical care: Learning from the COVID ‐19 pandemic
Objectives: SHIELD is a London‐based study of engagement in HIV clinical care during and after the COVID‐19 pandemic. We document the characteristics of service users who either re‐engaged or disengaged with HIV care, together with reflections of HIV clinical service‐providers to inform recommendations that address care retention for the long term. Methods: Using an exploratory mixed methods approach, service‐users aged ≥18 years who re‐engaged (1 March 2020–31 August 2020) or disengaged from clinical care (no contact with service 1 March 2020–28 February 2021) at 8 London HIV services were identified by retrospective records review. Demographics and clinical data were summarized descriptively. For people who re‐engaged, follow‐up data were collected at 24 months and in those who disengaged, at a single timepoint (1 March 2023). Semi‐structured interviews with clinic staff were analysed thematically. Results: There were 122 people disengaged and 89 re‐engaged. In those who re‐engaged, a 24‐month follow‐up showed 71.3% on antiretrovirals, 63.6% virally suppressed and 67.9% had a future clinician appointment booked. For people who disengaged, by 1 March 2023, 21% were on antiretrovirals and 27% had a future appointment booked. Interviews with 11 service providers explored COVID‐19's impact on clinical services, multilevel interactions that influenced engagement, and approaches to re‐engaging people. Conclusions: We found that COVID‐19 exposed existing vulnerabilities deterring access to HIV clinical care, as well as being itself an additional factor. For some people, the pandemic provided an opportunity to re‐engage. We recommend that retention in care is prioritized in policy and financially, that clinical services provide holistic person‐centred care, and improve ways to identify those who leave care.
- 31 December 2025
- Published by Wiley in HIV Medicine
- Vol. 27 (5) , 678-689
Open AccessSupporting long‐term engagement in HIV clinical care: Learning from the COVID ‐19 pandemic
Objectives: SHIELD is a London‐based study of engagement in HIV clinical care during and after the COVID‐19 pandemic. We document the characteristics of service users who either re‐engaged or disengaged with HIV care, together with reflections of HIV clinical service‐providers to inform recommendations that address care retention for the long term. Methods: Using an exploratory mixed methods approach, service‐users aged ≥18 years who re‐engaged (1 March 2020–31 August 2020) or disengaged from clinical care (no contact with service 1 March 2020–28 February 2021) at 8 London HIV services were identified by retrospective records review. Demographics and clinical data were summarized descriptively. For people who re‐engaged, follow‐up data were collected at 24 months and in those who disengaged, at a single timepoint (1 March 2023). Semi‐structured interviews with clinic staff were analysed thematically. Results: There were 122 people disengaged and 89 re‐engaged. In those who re‐engaged, a 24‐month follow‐up showed 71.3% on antiretrovirals, 63.6% virally suppressed and 67.9% had a future clinician appointment booked. For people who disengaged, by 1 March 2023, 21% were on antiretrovirals and 27% had a future appointment booked. Interviews with 11 service providers explored COVID‐19's impact on clinical services, multilevel interactions that influenced engagement, and approaches to re‐engaging people. Conclusions: We found that COVID‐19 exposed existing vulnerabilities deterring access to HIV clinical care, as well as being itself an additional factor. For some people, the pandemic provided an opportunity to re‐engage. We recommend that retention in care is prioritized in policy and financially, that clinical services provide holistic person‐centred care, and improve ways to identify those who leave care.
- Open Access
- 19 December 2024
- Published by Wiley in HIV Medicine
- Vol. 26 (3) , 465-478
Exploring the cascade of mental healthcare among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study
Introduction: Depressive symptoms are highly prevalent among people with HIV, which can negatively impact HIV‐related outcomes. We explore the cascade of mental healthcare for people with HIV experiencing depressive symptoms.Methods: People with HIV who were part of the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study (2013–2016) were included. A Patient Health Questionnaire‐9 (PHQ‐9) score ≥10 or Center for Epidemiologic Studies Depression Scale (CES‐D) ≥16 was defined as moderate/severe depressive symptoms. Diagnosed depression and access to mental healthcare were self‐reported. A cascade of mental healthcare was explored, defining individuals experiencing depressive symptoms; those among them reporting a diagnosis of depression; and of this latter group, the proportion reporting accessing mental healthcare. Demographic, social and clinical characteristics were assessed at each step using logistic regression.Results: Of the 1009 participants (65.5% ≥50 years, 85.8% male, 85.1% white), 387 (38.4%) individuals were experiencing depressive symptoms, over half of whom (54.3%) reported a diagnosis of depression. Only 43.3% of individuals with diagnosed depression reported accessing mental healthcare. Men [odds ratio = 0.62, 95% confidence interval (CI): 0.42–0.92], people in a relationship (0.44, 0.33–0.59), those who were employed (0.28, 0.21–0.38) and those with university qualifications (0.54, 0.40–0.72) were less likely to experience depressive symptoms. Heterosexuals (0.30, 0.14–0.64) were less likely to report a diagnosed depression, whereas smokers were more likely to have a diagnosed depression (1.75, 1.10–2.77). Older individuals (2.36, 1.31–4.28) were less likely to have accessed mental healthcare.Conclusions: Our findings suggest the presence of unmet mental healthcare needs for people with HIV. We hope these findings will inform policies to streamline mental health services for people with HIV.
- 19 December 2024
- Published by Wiley in HIV Medicine
- Vol. 26 (3) , 465-478
Open AccessExploring the cascade of mental healthcare among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study
Introduction: Depressive symptoms are highly prevalent among people with HIV, which can negatively impact HIV‐related outcomes. We explore the cascade of mental healthcare for people with HIV experiencing depressive symptoms.Methods: People with HIV who were part of the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study (2013–2016) were included. A Patient Health Questionnaire‐9 (PHQ‐9) score ≥10 or Center for Epidemiologic Studies Depression Scale (CES‐D) ≥16 was defined as moderate/severe depressive symptoms. Diagnosed depression and access to mental healthcare were self‐reported. A cascade of mental healthcare was explored, defining individuals experiencing depressive symptoms; those among them reporting a diagnosis of depression; and of this latter group, the proportion reporting accessing mental healthcare. Demographic, social and clinical characteristics were assessed at each step using logistic regression.Results: Of the 1009 participants (65.5% ≥50 years, 85.8% male, 85.1% white), 387 (38.4%) individuals were experiencing depressive symptoms, over half of whom (54.3%) reported a diagnosis of depression. Only 43.3% of individuals with diagnosed depression reported accessing mental healthcare. Men [odds ratio = 0.62, 95% confidence interval (CI): 0.42–0.92], people in a relationship (0.44, 0.33–0.59), those who were employed (0.28, 0.21–0.38) and those with university qualifications (0.54, 0.40–0.72) were less likely to experience depressive symptoms. Heterosexuals (0.30, 0.14–0.64) were less likely to report a diagnosed depression, whereas smokers were more likely to have a diagnosed depression (1.75, 1.10–2.77). Older individuals (2.36, 1.31–4.28) were less likely to have accessed mental healthcare.Conclusions: Our findings suggest the presence of unmet mental healthcare needs for people with HIV. We hope these findings will inform policies to streamline mental health services for people with HIV.
- Open Access
Pregnancy Management in HIV Viral Controllers: Twenty Years of Experience
(1) Background: The evidence base for the management of spontaneous viral controllers in pregnancy is lacking. We describe the management outcomes of pregnancies in a series of UK women with spontaneous HIV viral control ( 50 copies/mL) in 14/49 pregnancies (29%) (median 92, range 51–6084). Neonatal ZDV post-exposure prophylaxis was recorded for 45/49 infants. No transmissions were reported. (4) Conclusion: UK practice has been influenced by the change in guidelines, but this has had little impact on CS rates.
Open AccessPregnancy Management in HIV Viral Controllers: Twenty Years of Experience
(1) Background: The evidence base for the management of spontaneous viral controllers in pregnancy is lacking. We describe the management outcomes of pregnancies in a series of UK women with spontaneous HIV viral control ( 50 copies/mL) in 14/49 pregnancies (29%) (median 92, range 51–6084). Neonatal ZDV post-exposure prophylaxis was recorded for 45/49 infants. No transmissions were reported. (4) Conclusion: UK practice has been influenced by the change in guidelines, but this has had little impact on CS rates.
- 29 August 2023
- Published by Wiley in HIV Medicine
- Vol. 24 (12) , 1198-1209
Anticholinergic medications associated with falls and frailty in people with HIV
Background: Anticholinergic medications (ACMs) are associated with poorer age‐related outcomes, including falls and frailty. We investigate associations between ACM use and recurrent falls and frailty among older (aged ≥50 years) people with HIV in the POPPY study.Methods: Anticholinergic potential of co‐medications at study entry was coded using the anticholinergic burden score, anticholinergic risk score, and Scottish Intercollegiate Guidelines Network score; drugs scoring ≥1 on any scale were defined as ACM. Associations with recurrent falls (two or more falls in the previous 28 days) and frailty (modified Fried's) were assessed using logistic regression adjusting for (1) possible demographic/lifestyle confounders and (2) clinical factors and depressive symptoms (Patient Health Questionnaire‐9).Results: ACM use was reported by 193 (28%) of 699 participants, with 64 (9%) receiving two or more ACM; commonly prescribed ACMs were codeine (12%), citalopram (12%), loperamide (9%), and amitriptyline (7%). Falls were reported in 63/673 (9%), and 126/609 (21%) met the frailty criteria. Both recurrent falls and frailty were more common in ACM users than in non‐users (recurrent falls: 17% in users vs. 6% in non‐users, p < 0.001; frailty: 32% vs. 17%, respectively, p < 0.001). Use of two or more ACMs was associated with increased odds of falls after adjustment for demographic/lifestyle factors (odds ratio [OR] 4.53; 95% confidence interval [CI] 2.06–9.98) and for clinical factors (OR 3.58; 95% CI 1.37–9.38). Similar albeit weaker associations were seen with frailty (OR 2.26; 95% CI 1.09–4.70 and OR 2.12; 95% CI 0.89–5.0, respectively).Conclusions: ACM are commonly prescribed for people living with HIV, and evidence exists for an association with recurrent falls and frailty. Clinicians should be alert to this and reduce ACM exposure where possible.
- 29 August 2023
- Published by Wiley in HIV Medicine
- Vol. 24 (12) , 1198-1209
Anticholinergic medications associated with falls and frailty in people with HIV
Background: Anticholinergic medications (ACMs) are associated with poorer age‐related outcomes, including falls and frailty. We investigate associations between ACM use and recurrent falls and frailty among older (aged ≥50 years) people with HIV in the POPPY study.Methods: Anticholinergic potential of co‐medications at study entry was coded using the anticholinergic burden score, anticholinergic risk score, and Scottish Intercollegiate Guidelines Network score; drugs scoring ≥1 on any scale were defined as ACM. Associations with recurrent falls (two or more falls in the previous 28 days) and frailty (modified Fried's) were assessed using logistic regression adjusting for (1) possible demographic/lifestyle confounders and (2) clinical factors and depressive symptoms (Patient Health Questionnaire‐9).Results: ACM use was reported by 193 (28%) of 699 participants, with 64 (9%) receiving two or more ACM; commonly prescribed ACMs were codeine (12%), citalopram (12%), loperamide (9%), and amitriptyline (7%). Falls were reported in 63/673 (9%), and 126/609 (21%) met the frailty criteria. Both recurrent falls and frailty were more common in ACM users than in non‐users (recurrent falls: 17% in users vs. 6% in non‐users, p < 0.001; frailty: 32% vs. 17%, respectively, p < 0.001). Use of two or more ACMs was associated with increased odds of falls after adjustment for demographic/lifestyle factors (odds ratio [OR] 4.53; 95% confidence interval [CI] 2.06–9.98) and for clinical factors (OR 3.58; 95% CI 1.37–9.38). Similar albeit weaker associations were seen with frailty (OR 2.26; 95% CI 1.09–4.70 and OR 2.12; 95% CI 0.89–5.0, respectively).Conclusions: ACM are commonly prescribed for people living with HIV, and evidence exists for an association with recurrent falls and frailty. Clinicians should be alert to this and reduce ACM exposure where possible.
- 1 April 2023
- Published by SanovaWorks in Journal Of Drugs In Dermatology
- Vol. 22 (5) , 440-444
Non-Invasive Diagnosis of Sun Damaged Skin: Actinic Keratosis Vs Squamous Cell Carcinoma
Importance: Actinic keratosis (AK) is a premalignant lesion that has a1% to 10% potential of progression to squamous cell carcinoma (SCC), but it is not possible to determine which lesions are at higher risk. Objective: This study examined the epidermal genetic profiles of actinic keratosis and SCC through non-invasive techniques seeking to develop a biopsy-free method for AK monitoring and aid in the early diagnosis of developing SCC. Design: Ribonucleic acid (RNA) was collected from adhesive tape strips and gene expression levels were measured. A threshold fold change >2 and adjusted P-value 2 and adjusted P-value <0.05 was used for determination of differentially expressed genes. The differentially expressed genes that overlapped between the corrected and uncorrected groups were the most significant for analysis. Results: From 47 lesions, 6 significant differentially expressed genes were found between AK and SCC, and 25 significant differentially expressed genes between in-situ SCC and invasive SCC. Individual samples showed similarities based on diagnosis, suggesting mutations were specific to the disease and not the individual. Conclusions and Relevance: These findings highlight which genes may play a role in AK progression to SCC. The genomic differences between in-situ and invasive squamous cell carcinoma open an opportunity for early diagnosis of squamous cell carcinoma and risk prediction of actinic keratosis. J Drugs Dermatol. 2023;22(5): doi:10.36849/JDD.7097 Majidian M, Anderson J, Rock JA, et al. Non-Invasive Diagnosis of Sun Damaged Skin: Actinic Keratosis Versus Squamous Cell Carcinoma. J Drugs Dermatol. 2023;22(5):440-444. doi:10.36849/JDD.7097Sun Damaged, Actinic Keratosis, Squamous Cell Carcinoma
- 1 April 2023
- Published by SanovaWorks in Journal Of Drugs In Dermatology
- Vol. 22 (5) , 440-444
Non-Invasive Diagnosis of Sun Damaged Skin: Actinic Keratosis Vs Squamous Cell Carcinoma
Importance: Actinic keratosis (AK) is a premalignant lesion that has a1% to 10% potential of progression to squamous cell carcinoma (SCC), but it is not possible to determine which lesions are at higher risk. Objective: This study examined the epidermal genetic profiles of actinic keratosis and SCC through non-invasive techniques seeking to develop a biopsy-free method for AK monitoring and aid in the early diagnosis of developing SCC. Design: Ribonucleic acid (RNA) was collected from adhesive tape strips and gene expression levels were measured. A threshold fold change >2 and adjusted P-value 2 and adjusted P-value <0.05 was used for determination of differentially expressed genes. The differentially expressed genes that overlapped between the corrected and uncorrected groups were the most significant for analysis. Results: From 47 lesions, 6 significant differentially expressed genes were found between AK and SCC, and 25 significant differentially expressed genes between in-situ SCC and invasive SCC. Individual samples showed similarities based on diagnosis, suggesting mutations were specific to the disease and not the individual. Conclusions and Relevance: These findings highlight which genes may play a role in AK progression to SCC. The genomic differences between in-situ and invasive squamous cell carcinoma open an opportunity for early diagnosis of squamous cell carcinoma and risk prediction of actinic keratosis. J Drugs Dermatol. 2023;22(5): doi:10.36849/JDD.7097 Majidian M, Anderson J, Rock JA, et al. Non-Invasive Diagnosis of Sun Damaged Skin: Actinic Keratosis Versus Squamous Cell Carcinoma. J Drugs Dermatol. 2023;22(5):440-444. doi:10.36849/JDD.7097Sun Damaged, Actinic Keratosis, Squamous Cell Carcinoma
- Open Access
- 15 March 2023
- Published by Wiley in HIV Medicine
- Vol. 24 (S2) , 8-19
Long‐term success for people living with HIV: A framework to guide practice
Objectives: In recent decades, the needs of people living with HIV have evolved as life expectancy has greatly improved. Now, a new definition of long‐term success (LTS) is necessary to help address the multifaceted needs of all people living with HIV.Methods: We conducted a two‐phase research programme to delineate the range of experiences of people living with HIV. The insights garnered from these research phases were explored in a series of expert‐led workshops, which led to the development and refinement of the LTS framework.Results: The insights generated from the research phases identified a series of themes that form a part of LTS. These themes were subsequently incorporated into the LTS framework, which includes five outcome pillars: sustained undetectable viral load, minimal impact of treatment and clinical monitoring, optimized health‐related quality of life, lifelong integration of healthcare, and freedom from stigma and discrimination. A series of supporting statements were also developed by the expert panel to help in the achievement of each of the LTS pillars.Conclusions: The LTS framework offers a comprehensive and person‐centric approach that, if achieved, could help improve the long‐term well‐being of people living with HIV and support the LTS vision of ‘every person living with HIV being able to live their best life’.
- 15 March 2023
- Published by Wiley in HIV Medicine
- Vol. 24 (S2) , 8-19
Open AccessLong‐term success for people living with HIV: A framework to guide practice
Objectives: In recent decades, the needs of people living with HIV have evolved as life expectancy has greatly improved. Now, a new definition of long‐term success (LTS) is necessary to help address the multifaceted needs of all people living with HIV.Methods: We conducted a two‐phase research programme to delineate the range of experiences of people living with HIV. The insights garnered from these research phases were explored in a series of expert‐led workshops, which led to the development and refinement of the LTS framework.Results: The insights generated from the research phases identified a series of themes that form a part of LTS. These themes were subsequently incorporated into the LTS framework, which includes five outcome pillars: sustained undetectable viral load, minimal impact of treatment and clinical monitoring, optimized health‐related quality of life, lifelong integration of healthcare, and freedom from stigma and discrimination. A series of supporting statements were also developed by the expert panel to help in the achievement of each of the LTS pillars.Conclusions: The LTS framework offers a comprehensive and person‐centric approach that, if achieved, could help improve the long‐term well‐being of people living with HIV and support the LTS vision of ‘every person living with HIV being able to live their best life’.
- Open Access
- 15 March 2023
- Published by Wiley in HIV Medicine
- Vol. 24 (S2) , 3-7
Why we need to re‐define long‐term success for people living with HIV
Over the past few decades, the life expectancy of people living with HIV has markedly improved due to the advances in HIV diagnosis, linkage to care, and treatment. However, with these advances, a new set of challenges has emerged that must be addressed to ensure the long‐term well‐being of people living with HIV. In this article, as part of a wider journal supplement, we explore the unmet needs and challenges across the HIV continuum of care and re‐define what long‐term success looks like to support the healthy ageing of all people affected by HIV.
- 15 March 2023
- Published by Wiley in HIV Medicine
- Vol. 24 (S2) , 3-7
Open AccessWhy we need to re‐define long‐term success for people living with HIV
Over the past few decades, the life expectancy of people living with HIV has markedly improved due to the advances in HIV diagnosis, linkage to care, and treatment. However, with these advances, a new set of challenges has emerged that must be addressed to ensure the long‐term well‐being of people living with HIV. In this article, as part of a wider journal supplement, we explore the unmet needs and challenges across the HIV continuum of care and re‐define what long‐term success looks like to support the healthy ageing of all people affected by HIV.
- Open Access
- 28 March 2022
- Published by Wiley in HIV Medicine
- Vol. 23 (10) , 1098-1102
Covid‐19 First Wave Impact National Survey for HIV Clinicians by Public Health England (PHE), the British HIV Association (BHIVA) and the Children’s HIV Association (CHIVA)
This short report describes the results of a survey that was developed by Public Health England (PHE), the British HIV Association (BHIVA) and the Children's HIV Association (CHIVA) and circulated to all UK national health service HIV providers in the UK following the first wave of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; coronavirus disease 2019 [COVID‐19]) pandemic to assess the impact of the pandemic on HIV clinics. The survey was created by BHIVA/CHIVA and PHE and was piloted prior to circulation to all HIV clinics within the UK on 3 July 2020. The survey questions were designed to assess the impact of the first wave of COVID‐19 on HIV clinics and lead/senior HIV clinicians. Clinicians’ responses were collected between 3 July 2020 and 17 September 2020. The survey responses were collated, and non‐statistical analysis was performed. The results of the survey confirmed that services had undergone substantial changes, including a shift from face‐to‐face consults to predominantly virtual consultations. Some clinicians’ responses suggested that the first wave had many negative effects on people living with HIV, including their ability to access mental health services. The first wave of COVID‐19 caused significant changes to HIV services within the UK. There was a shift toward the use of technology in healthcare, and results from subsequent clinician surveys carried out since the first wave of COVID‐19 will reflect the ongoing transformation of care towards a more virtual service.
- 28 March 2022
- Published by Wiley in HIV Medicine
- Vol. 23 (10) , 1098-1102
Open AccessCovid‐19 First Wave Impact National Survey for HIV Clinicians by Public Health England (PHE), the British HIV Association (BHIVA) and the Children’s HIV Association (CHIVA)
This short report describes the results of a survey that was developed by Public Health England (PHE), the British HIV Association (BHIVA) and the Children's HIV Association (CHIVA) and circulated to all UK national health service HIV providers in the UK following the first wave of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; coronavirus disease 2019 [COVID‐19]) pandemic to assess the impact of the pandemic on HIV clinics. The survey was created by BHIVA/CHIVA and PHE and was piloted prior to circulation to all HIV clinics within the UK on 3 July 2020. The survey questions were designed to assess the impact of the first wave of COVID‐19 on HIV clinics and lead/senior HIV clinicians. Clinicians’ responses were collected between 3 July 2020 and 17 September 2020. The survey responses were collated, and non‐statistical analysis was performed. The results of the survey confirmed that services had undergone substantial changes, including a shift from face‐to‐face consults to predominantly virtual consultations. Some clinicians’ responses suggested that the first wave had many negative effects on people living with HIV, including their ability to access mental health services. The first wave of COVID‐19 caused significant changes to HIV services within the UK. There was a shift toward the use of technology in healthcare, and results from subsequent clinician surveys carried out since the first wave of COVID‐19 will reflect the ongoing transformation of care towards a more virtual service.